NCT02893917 2026-03-18
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT00436956 2018-10-09
AZD2171 to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00527124 2018-08-09
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01260688 2018-08-08
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
National Cancer Institute (NCI)
Phase 2 Completed
NCT00423332 2017-02-02
Cediranib (AZD2171, RECENTINâ„¢) in Metastatic or Recurrent Renal Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00227760 2016-02-29
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00303862 2014-05-21
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated